BIO KEY INTERNATIONAL INC (BKYI): Nasdaq/NYSE listing notice — BIO-key receives Nasdaq non-compliance notice for late 10-K filing

BIO KEY INTERNATIONAL INC

Nasdaq notified BIO-key on April 18, 2023, of non-compliance with Listing Rule 5250(c)(1) due to failure to file annual 10-K for FY2022.
Company has 60 days to submit a compliance plan; Nasdaq may grant up to 180 days extension until October 16, 2023.
Late filing attributed to compilation and review delays deemed undue hardship; no immediate effect on stock listing.
BIO-key intends to file the 10-K as soon as practicable to regain compliance.

item 3.01 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

BIO KEY INTERNATIONAL INC received a nasdaq deficiency notice notice regarding late filing (rules 5250(c)(1)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: late filing
Rules: 5250(c)(1)

Exact text from the filing

April 18, 2023, BIO-key International, Inc. (the “Company”) received notice from The Nasdaq Stock Market, LLC (“Nasdaq”) indicating that the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1), which requires listed companies to timely file all required periodic financial reports with the Securities and Exchange Commission (“SEC”), due to the Company’s failure to timely file its Annual Report on Form 10-K for the fiscal year ended December 31, 2022 (the “Form 10-K”). The notification letter has no immediate effect on the listing or trading of the Company’s common stock on the Nas

View on SEC.gov

5 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

BIO KEY INTERNATIONAL INC filing history →

Source: SEC EDGAR

accession 0001437749-23-010926

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.